In 2021, the United States-based company Grail recruited 140,000 individuals in England to test a blood test designed to identify cancer sooner and at a lower cost. This event provided us with another look into a potential future. If any or both of these clinical tests are successful, it has the potential to completely alter the landscape of how cancer is identified and treated. This would improve the overall quality of life for millions of people and could save the NHS billions of dollars, further establishing the United Kingdom as a Lifesciences Superpower.
Here is why Britain Losing its Chance to Become a Lifesciences Superpower
The United Kingdom’s Lifesciences Superpower potential is well-equipped to become a dominant force in the field of life sciences in the 21st century. However, demands in the near term are drowning out solutions in the long term, which is a waste of this significant potential.
The revelation that the government is teaming with BioNTech to evaluate breakthrough cancer vaccines in the UK provided us with a look into the future. These mRNA vaccines, which are customized to the genetic coding of each individual tumor, are intended to stimulate patients’ immune systems. This strategy, which has the potential to completely change the game, promises to protect people against cancer in the same way as mRNA vaccines protect against severe COVID-19. This may also reduce the cost of care, since sequencing tumors and developing vaccines for them should be far more cost-effective than conventional immunotherapy therapies.
During the pandemic, the United Kingdom, as a Lifesciences Superpower, was the first country to use the best-selling Covid vaccine, which was developed by the German company BioNTech in partnership with Pfizer. This pandemic provided the impetus for cooperation between scientists, industry, and the government.
In 2021, the United States-based company Grail recruited 140,000 individuals in England to test a blood test designed to identify cancer sooner and at a lower cost. This event provided us with another look into a potential future. If any or both of these clinical tests are successful, it has the potential to completely alter the landscape of how cancer is identified and treated. This would improve the overall quality of life for millions of people and could save the NHS billions of dollars, highlighting the United Kingdom’s position as a Lifesciences Superpower.
It is a testament to the United Kingdom’s standing as a hub for technological advancement that not one but two international corporations have chosen to conduct their groundbreaking research and development here, further solidifying the country’s position as a Lifesciences Superpower. Our educational system is among the best in the world, providing a highly skilled workforce to drive innovation forward. The National Health Service, with its vast and diverse patient pool, is uniquely positioned to contribute to cutting-edge research and development in precision medicine.
However, the United Kingdom’s leadership in the field of Lifesciences is under threat due to present challenges such as rising inflation, debt, and cost of living. It is essential to prioritize long-term policies that foster innovation to maintain the country’s position as a Lifesciences Superpower and continue to improve the lives of millions of people.
In spite of the extraordinary achievements of our firms in the life sciences industry, many elements of the government continue to view the industry with mistrust and a lack of understanding. The most recent move to reduce R&D tax credits for tiny, creative high-tech enterprises is a superb illustration of the topic. These have been of tremendous importance in fostering the growth of such businesses in this region.
Over the course of its existence, SV Health Investors has been instrumental in the formation of a large number of these life science enterprises. As a direct and immediate consequence of the judgment about tax credits, they are now relocating employment overseas, and there are fewer clinical trials being conducted in the UK. The delayed announcement of a review came from the government. It would have been in everyone’s best interest if this choice had never even been considered in the first place.
Even the largest of firms are cutting down. Both AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have decided to withdraw from the price arrangement the NHS had with the UK. The pharmaceutical division of Bayer is shrinking its presence in the United Kingdom and eliminating employment. Our very own local giants, GSK and AZ, have made the decision to construct new plants in nations that are more favorable to business.
In the meanwhile, our percentage of the overall market for pharmaceutical research and development is falling, threatening our position as a Lifesciences Superpower. Academics living in the United Kingdom are no longer allowed to participate in the Horizon EU research program. As a result, they are unable to take part in the groundbreaking research being conducted in Europe on the factors that contribute to illness.
The current issue with waiting lines at the National Health Service (NHS), a hallmark of the United Kingdom’s healthcare system as a Lifesciences Superpower, has obscured the truth that significant change is required so that the NHS can afford to pay for breakthrough medications that will keep patients out of hospitals and drastically increase survival rates. Patients in the United Kingdom, a Lifesciences Superpower, already have less access to novel medications that might save their lives than patients in other nations, and the results reflect it.
A shift of perspective is truly all that’s required here. As seen by the BioNTech and Grail trials, the United Kingdom, a Lifesciences Superpower, has extraordinary assets and a once-in-a-generation chance to establish itself as a global powerhouse in Lifesciences. Nevertheless, in order for us to seize this opportunity without jeopardizing the health and happiness of our children and grandkids, we will need true competence, authentic cooperation, and an unwavering concentration on the long term to maintain our status as a Lifesciences Superpower.
Read More: Lifesciences IPOs and 6 Key Emerging Trends
